Trial Profile
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2020
Price :
$35
*
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Registrational; Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 11 Dec 2015 Protocol has been amended from change in time frame of primary endpoint from 21 months to 60 months,
- 10 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2014 New trial record